VHL rs5030807: Understanding This Hereditary Cancer Variant
The rs5030807 variant is a specific change in the VHL gene associated with an increased risk for Von Hippel-Lindau (VHL) syndrome. This condition is a hereditary disorder that predisposes individuals to the development of various tumors and cysts throughout the body.
What each genotype means
Typical VHL gene profile
This is the most common genotype observed in the general population. It is considered the reference sequence for the VHL gene at this position.
This is the most common genotype found in the general population.
Potential VHL mutation carrier
This genotype represents a known missense mutation (p.Leu89Pro) in the VHL gene. Research associates this variant with an increased risk for Von Hippel-Lindau syndrome, a condition that can lead to various cysts and tumors, including renal cell carcinoma. Because clinical manifestations are highly variable even within families, you should discuss these findings with a genetic counselor or physician to determine if clinical surveillance is appropriate.
This is a rare genotype found at very low frequencies in global population databases.
What is rs5030807?
The variant rs5030807 is a single nucleotide polymorphism (SNP) located on chromosome 3 within the VHL gene. In genetic terms, this specific change is often referred to as a missense mutation, specifically p.Leu89Pro, where the amino acid leucine is replaced by proline in the resulting protein. Because the VHL gene is critical for tumor suppression, changes in its sequence can disrupt the normal function of the protein it encodes. This variant is categorized as a pathogenic mutation in clinical databases, meaning it is recognized for its potential to contribute to disease development. It is important to note that genetic variants are identified by their specific location and the nature of the change, and rs5030807 is one of many known variants within this gene that have been studied for their impact on human health.
The Role of the VHL Gene
The VHL gene provides instructions for making a protein that acts as a tumor suppressor. This protein is a key component of an E3 ubiquitin ligase complex, which plays a vital role in the body's response to low oxygen levels, or hypoxia. Under normal conditions, the VHL protein helps regulate the degradation of hypoxia-inducible factors (HIFs). When oxygen levels are sufficient, the VHL protein marks these factors for destruction. If the VHL protein is dysfunctional due to a mutation, these factors can accumulate inappropriately, leading to the overproduction of proteins that promote blood vessel growth and cell proliferation. This disruption is a fundamental mechanism in the development of tumors, as it allows cells to grow and divide without the usual regulatory checks, which is why VHL mutations are strongly linked to hereditary cancer syndromes.
Research and Clinical Associations
Research has established a strong association between pathogenic variants in the VHL gene and Von Hippel-Lindau syndrome, an autosomal dominant condition. Individuals with this syndrome are at an increased risk for developing various growths, including hemangioblastomas of the central nervous system, retinal angiomas, pheochromocytomas, and clear cell renal cell carcinoma. The evidence for the pathogenicity of variants like rs5030807 is considered moderate to strong in clinical literature, as it is frequently identified in patients presenting with these clinical features. Because VHL syndrome is inherited in an autosomal dominant pattern, an individual only needs to inherit one copy of a pathogenic variant to be at risk. However, the clinical expression of the syndrome can be highly variable, meaning that even within the same family, individuals may experience different types of tumors or varying degrees of disease severity.
Population Frequency
The rs5030807 variant is considered rare in the general population. Because it is associated with a specific hereditary syndrome, it is not a common polymorphism found in the general public. Most individuals do not carry this variant. When it is identified, it is typically through targeted genetic testing performed after a clinical diagnosis of VHL syndrome or as part of a family screening process following the identification of a mutation in a relative. Due to its rarity, population-wide frequency data is limited, and the presence of this variant is generally investigated in the context of clinical genetics rather than population health screening.
Navigating Genetic Information
If you have received information regarding the presence of rs5030807, it is essential to consult with a qualified healthcare professional, such as a genetic counselor or a medical geneticist. Genetic information is complex, and a professional can help interpret what this means for your specific health profile and family history. You should never use genetic test results to make independent medical decisions or diagnoses. A clinician can provide guidance on appropriate surveillance, screening protocols, and the potential need for testing other family members. Genetic counseling provides a supportive environment to discuss the implications of these findings, including the psychological and medical aspects of managing a hereditary cancer predisposition. Always rely on clinical confirmation from a laboratory and a discussion with your doctor before taking any action based on genetic data.
How common is this variant?
The rs5030807 variant is rare in the general population, as it is a pathogenic mutation associated with a specific hereditary syndrome.
Frequently asked questions
What is Von Hippel-Lindau syndrome?
Von Hippel-Lindau (VHL) syndrome is a rare, inherited disorder that causes tumors and cysts to grow in various parts of the body. These growths can be benign or cancerous and often affect the kidneys, brain, and eyes.
Is rs5030807 a cancer diagnosis?
No, identifying a genetic variant is not a cancer diagnosis. It indicates a hereditary predisposition, meaning you have a higher risk of developing certain conditions, but it does not mean you currently have cancer or will definitely develop it.
Should I get tested for this variant?
Genetic testing for VHL is typically recommended if you have a personal or family history of tumors associated with the syndrome. You should discuss the necessity of testing with a genetic counselor or your primary care physician.
What should I do if I have this variant?
If you are confirmed to have a pathogenic VHL variant, your doctor will likely recommend a specialized surveillance program. This may include regular imaging, such as MRIs or ultrasounds, to monitor for the development of tumors.
Sources & further reading
Educational information only, last refreshed 9/15/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs5030807?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in VHL
A pathogenic variant in the VHL gene causing Von Hippel-Lindau disease.
Pathogenic missense variant (p.Arg167Gln) associated with von Hippel-Lindau disease.
Predisposes to von Hippel-Lindau disease, increasing the lifetime risk of clear cell renal carcinomas and pheochromocytomas.